FDA accepts PTC Therapeutics’ NDA for Sepiapterin, aiming for breakthrough in PKU treatment

PTC Therapeutics, Inc. has announced a significant step forward in its mission to combat phenylketonuria (PKU) by receiving FDA acceptance for the New Drug Application (NDA) of Sepiapterin. The acceptance of this NDA, supported by positive clinical trial results, brings much-needed hope to patients managing this rare metabolic disorder. The FDA’s action sets a critical milestone, potentially leading to new treatment options for both pediatric and adult PKU patients.

PKU is a severe inherited disorder that inhibits the breakdown of phenylalanine, an amino acid found in most proteins. If left untreated, PKU can result in irreversible neurological damage, including intellectual disability and seizures. The standard treatment involves strict dietary restrictions to prevent phenylalanine buildup. However, Sepiapterin offers an alternative, showing significant promise by improving phenylalanine levels and potentially allowing for more liberalized diets.

In clinical trials, Sepiapterin demonstrated a 63% mean reduction in blood phenylalanine levels, with even more impressive results among classical PKU patients. The drug works through a dual mechanism, increasing the critical cofactor tetrahydrobiopterin (BH4) and enhancing the function of the deficient PAH enzyme. This innovative approach could provide a substantial improvement in the quality of life for PKU patients.

Further analysis from the ongoing trials, including the Phe tolerance sub-study, shows that Sepiapterin not only controls phenylalanine but also allows patients to increase their protein intake without compromising their condition. This aspect of the drug could relieve the dietary burden that many patients have faced for years.

Catherine Warren of the National PKU Alliance expressed her excitement about this development, noting that families have long been waiting for a treatment that eases their dependence on restrictive diets. PTC Therapeutics CEO Matthew B. Klein added that the NDA acceptance is a vital milestone, potentially leading to a new option for patients with limited choices in managing their disease.

As the FDA moves forward with its review, the PKU community remains hopeful for a future where diet restrictions are eased, and phenylalanine levels are better controlled, improving the lives of those affected by this rare disease.